Voltron Therapeutics
Precision-guided vaccines enhancing cell-mediated responses for cancer and infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $5.9m | Grant | |
| Total Funding | 000k | ||
Related Content
Voltron Therapeutics, Inc., founded in 2017, is a biotechnology company focused on developing advanced vaccines for cancer and infectious diseases. Utilizing the proprietary Self Assembling Vaccine Design technology, licensed exclusively from Massachusetts General Hospital and the Vaccine Immunotherapy Center, Voltron aims to improve cell-mediated immune responses. The company targets both oncology and emerging infectious diseases, with initial proof of concept demonstrated in pre-clinical studies for Lassa Fever, Q Fever, ovarian cancer, and HPV-related cancers. Voltron's business model revolves around leveraging cutting-edge research to create effective vaccines, serving healthcare providers and patients in the oncology and infectious disease markets. Revenue is generated through licensing agreements, research grants, and potential future sales of developed vaccines.
Keywords: biotechnology, vaccines, oncology, infectious diseases, cell-mediated immunity, proprietary technology, pre-clinical studies, healthcare, Massachusetts General Hospital, exclusive license.